---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-062742"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:02:26.129299+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics stockholders approve 20x authorized share increase to 2B; massive dilution authorized

## Summary
- Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.
- Stockholders approved issuance of up to 1.26B shares upon exercise of Series B Warrants with zero exercise price.
- Warrant exercise price reset to floor of $0.132; Series A/B could total ~1.68B shares if fully exercised.
- All proposals passed with >88% votes for; quorum of 8.2M shares out of 11.8M outstanding.
- Item 8.01 confirms massive potential equity dilution from prior private placement warrants.

## SEC filing metadata
- accession: 0000950170-25-062742
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- confidence: high
- sec_items: 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017025062742/0000950170-25-062742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017025062742/pstv-20250502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-062742
- JSON: https://secwatch.observer/filing/0000950170-25-062742.json
- Plain text: https://secwatch.observer/filing/0000950170-25-062742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.